Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Metastatic Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02091960
What this trial is testing

Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Who this might be right for
HER2 AmplifiedAdvanced Breast CancerHuman Epidermal Growth Factor Receptor 2 (HER2)
Astellas Pharma Global Development, Inc. 103
Testing effectiveness (Phase 2)Active Not RecruitingNCT02398773
What this trial is testing

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Who this might be right for
HER2/Neu NegativeProgesterone Receptor NegativeProgesterone Receptor Positive+1 more
National Cancer Institute (NCI) 99
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07785856
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer

Who this might be right for
T-dxd Resistant HER2-PositiveHER2 Low Metastatic Breast Cancer
The Methodist Hospital Research Institute 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT04762979
What this trial is testing

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CarcinomaHER2-negative Breast CancerPIK3CA Mutant Metastatic Breast Cancer
Marina N Sharifi 44
Early research (Phase 1)Study completedNCT01423123
What this trial is testing

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
NSABP Foundation Inc 21
Not applicableStudy completedNCT06168227
What this trial is testing

And Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 150
Testing effectiveness (Phase 2)UnknownNCT04001621
What this trial is testing

Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Fudan University 100
Testing effectiveness (Phase 2)Ended earlyNCT05966584
What this trial is testing

Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 1
Testing effectiveness (Phase 2)Study completedNCT00386685
What this trial is testing

XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Sanofi 51
Testing effectiveness (Phase 2)Ended earlyNCT00453635
What this trial is testing

Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 88
Testing effectiveness (Phase 2)Ended earlyNCT03709082
What this trial is testing

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerBreast Cancer Metastatic
University of Kansas Medical Center 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT04214288
What this trial is testing

Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

Who this might be right for
Advanced ER-Positive HER2-Negative Breast Cancer
AstraZeneca 240
Early research (Phase 1)Study completedNCT03455270
What this trial is testing

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast Cancer FemaleBreast Neoplasm+4 more
G1 Therapeutics, Inc. 107
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07235618
What this trial is testing

Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University 50
Testing effectiveness (Phase 2)Study completedNCT04505826
What this trial is testing

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
Olema Pharmaceuticals, Inc. 153
Testing effectiveness (Phase 2)Looking for participantsNCT06224673
What this trial is testing

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more
Laura Huppert, MD, BA 36
Not applicableLooking for participantsNCT07030569
What this trial is testing

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Who this might be right for
RadiomicRadiomicsBreast Cancer Metastatic+13 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07824869
What this trial is testing

A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients

Who this might be right for
HER2 + Breast Cancer
Shanghai Henlius Biotech 90
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Testing effectiveness (Phase 2)Ended earlyNCT03584009
What this trial is testing

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Who this might be right for
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 103
Next Page